U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C15H9FN2.BrH
Molecular Weight 317.156
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of MFZ10-7 hydrobromide

SMILES

Br.CC1=NC(=CC=C1)C#CC2=CC(=CC(F)=C2)C#N

InChI

InChIKey=OEELBDJXBNRCRD-UHFFFAOYSA-N
InChI=1S/C15H9FN2.BrH/c1-11-3-2-4-15(18-11)6-5-12-7-13(10-17)9-14(16)8-12;/h2-4,7-9H,1H3;1H

HIDE SMILES / InChI
Molecular Formula BrH
Molecular Weight 80.912
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula C15H9FN2
Molecular Weight 236.2438
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

MFZ 10-7 is a high affinity negative allosteric modulator at the mGlu5 receptor (Ki = 0.67 nM). MFZ 10-7 demonstrates anxyolitic properties in mouse models. Intraperitoneal administration of MFZ 10-7 inhibited intravenous cocaine self-administration, cocaine-induced reinstatement of drug-seeking behavior and cocaine-associated cue-induced cocaine-seeking behavior in rats.

CNS Activity

Originator

Approval Year

Unknown
139594
Targets

Targets

Primary TargetPharmacologyConditionPotency
Metabotropic glutamate receptor 5
39
Target ID: P41594
Gene ID: 2915.0
Gene Symbol: GRM5
Target Organism: Homo sapiens (Human)
Antagonist
2778
 1.22 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Preclinical
Unknown

Approved Use

Unknown
Primary
Preclinical
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Metabotropic glutamate receptor 5 negative allosteric modulators as novel tools for in vivo investigation.
2012 Jul 12
A novel mGluR5 antagonist, MFZ 10-7, inhibits cocaine-taking and cocaine-seeking behavior in rats.
2014 Mar
Patents

Patents

US-20110190505-A1
3
WO-2010048170-A2
3

Sample Use Guides

In Vivo Use Guide
For anxyolitic tests MFZ 10-7 was delivered via ip injection 15 min prior to testing. Anxyolitic effects were observed at dose 0.3 mg/kg.
Route of Administration: Intraperitoneal
In Vitro Use Guide
MFZ 10-7 was evaluated for antagonism of glutamate-mediated mobilization of internal calcium in an mGluR5 in vitro assay. MFZ 10-7 (compound 2d) inhibited mGluR5 with IC50 1.22 nM.
Substance Class Chemical
Created
by admin
on Sat Dec 16 19:19:53 GMT 2023
Edited
by admin
on Sat Dec 16 19:19:53 GMT 2023
Record UNII
VQ47T8DE6U
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
MFZ10-7 hydrobromide
Common Name English
Benzonitrile, 3-fluoro-5-[2-(6-methyl-2-pyridinyl)ethynyl]-, hydrobromide (1:1)
Systematic Name English
MFZ-10-7 hydrobromide
Common Name English
Code System Code Type Description
FDA UNII
VQ47T8DE6U
Created by admin on Sat Dec 16 19:19:53 GMT 2023 , Edited by admin on Sat Dec 16 19:19:53 GMT 2023
PRIMARY
CAS
1380072-52-5
Created by admin on Sat Dec 16 19:19:53 GMT 2023 , Edited by admin on Sat Dec 16 19:19:53 GMT 2023
PRIMARY
PUBCHEM
166177251
Created by admin on Sat Dec 16 19:19:53 GMT 2023 , Edited by admin on Sat Dec 16 19:19:53 GMT 2023
PRIMARY
Related Record Type Details
Structure of MFZ10-7
PARENT -> SALT/SOLVATE
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966